The combination of donor and ZFNs demonstrated here is able to truncate BCR-ABL oncoprotein efficiently in CML cells and CML CD34+ cells and show the anti-leukemia ability in vitro and in vivo. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.